United Kingdom · Question · Written question
UIN 161294
Voluntary Scheme for Branded Medicines Pricing and Access
Introduced
8 March 2023
Last action
17 March 2023 · Answer
Status
Answered
Sponsors
—
Subjects
Discovery layer
Source updated
17 March 2023
Summary
To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential impact of the payment rates under the Voluntary Scheme for Branded Medicines Pricing and Access on the level of research and development in the UK, incl
This text is taken from the official record. PoliticalRepo does not editorialize.
Timeline
8 March 2023
Written question
To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential impact of the payment rates under the Voluntary Scheme for Branded Medicines Pricing and Access on the level of research and development in the UK, incl
Source: Commons
17 March 2023
Answer
The Government has assessed the link between the volume-based rebate payments in our medicine pricing schemes and various kinds of investment in our impact assessment of recent updates to the statutory scheme for branded medicines pricing, which operates ...
Source: Written answer
Votes
No vote records are attached yet.
Versions
No version snapshots stored. Document URLs remain at the source.
Documents
No documents linked.
Sponsors
- · Department of Health and Social Care · Answering body
Related records
No cross-record relationships stored yet.
Sources
PoliticalRepo is an index and interpretation layer, not the authoritative legal source.
- Official source: https://questions-statements.parliament.uk/written-questions/detail/2023-03-08/161294
- Open data entity: https://questions-statements-api.parliament.uk/api/writtenquestions/questions/1602404
- uk · wq-1602404 · source updated 17 March 2023